252 related articles for article (PubMed ID: 33490226)
1. Current and future immunotherapy approaches in ovarian cancer.
Demircan NC; Boussios S; Tasci T; Öztürk MA
Ann Transl Med; 2020 Dec; 8(24):1714. PubMed ID: 33490226
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
Lee L; Matulonis U
Gynecol Oncol; 2019 Jul; 154(1):236-245. PubMed ID: 30995960
[TBL] [Abstract][Full Text] [Related]
3. Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Lorusso D; Ceni V; Muratore M; Salutari V; Nero C; Pietragalla A; Ciccarone F; Carbone V; Daniele G; Scambia G
Expert Opin Emerg Drugs; 2020 Dec; 25(4):445-453. PubMed ID: 33040627
[TBL] [Abstract][Full Text] [Related]
4. Future of immune checkpoint inhibitors: focus on tumor immune microenvironment.
Jia Y; Liu L; Shan B
Ann Transl Med; 2020 Sep; 8(17):1095. PubMed ID: 33145314
[TBL] [Abstract][Full Text] [Related]
5. Genetic and epigenetic strategies for advancing ovarian cancer immunotherapy.
Cho Y; Milane L; Amiji MM
Expert Opin Biol Ther; 2019 Jun; 19(6):547-560. PubMed ID: 30933545
[TBL] [Abstract][Full Text] [Related]
6. Current status of cancer immunotherapy for gynecologic malignancies.
Nishio H; Iwata T; Aoki D
Jpn J Clin Oncol; 2021 Feb; 51(2):167-172. PubMed ID: 33244581
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Epithelial Ovarian Cancer: An Overview on Efficacy and Future Perspectives.
Borella F; Ghisoni E; Giannone G; Cosma S; Benedetto C; Valabrega G; Katsaros D
Diagnostics (Basel); 2020 Mar; 10(3):. PubMed ID: 32156035
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
10. Ovarian Cancer Immunotherapy: Turning up the Heat.
Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint inhibitors in ovarian cancer: A review of preclinical data.
Doo DW; Norian LA; Arend RC
Gynecol Oncol Rep; 2019 Aug; 29():48-54. PubMed ID: 31312712
[TBL] [Abstract][Full Text] [Related]
12. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma.
Choi C; Yoo GS; Cho WK; Park HC
World J Gastroenterol; 2019 May; 25(20):2416-2429. PubMed ID: 31171886
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy in gynecological cancers.
Lorusso D; Ceni V; Daniele G; Pietragalla A; Salutari V; Muratore M; Nero C; Ciccarone F; Scambia G
Explor Target Antitumor Ther; 2021; 2(1):48-64. PubMed ID: 36046088
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells.
Nham T; Poznanski SM; Fan IY; Shenouda MM; Chew MV; Lee AJ; Vahedi F; Karimi Y; Butcher M; Lee DA; Hirte H; Ashkar AA
Cancer Immunol Immunother; 2018 Apr; 67(4):575-587. PubMed ID: 29299659
[TBL] [Abstract][Full Text] [Related]
17. Application Of Adoptive Immunotherapy In Ovarian Cancer.
Yang S; Yin X; Yue Y; Wang S
Onco Targets Ther; 2019; 12():7975-7991. PubMed ID: 31632055
[TBL] [Abstract][Full Text] [Related]
18. Checkpoint inhibitors in immunotherapy of ovarian cancer.
Wang DH; Guo L; Wu XH
Tumour Biol; 2015 Jan; 36(1):33-9. PubMed ID: 25409618
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
20. Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
Guo H; He Y; Chen P; Wang L; Li W; Chen B; Liu Y; Wang H; Zhao S; Zhou C
J Thorac Dis; 2020 Oct; 12(10):6070-6089. PubMed ID: 33209440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
